Sail Biomedicine’s $925 million deal with Johnson & Johnson helped boost the cell and gene therapy sector over biologics in terms of venture capital fundraising in the third quarter.
Cell therapy investment grows as safety events rankle Big Pharma’s CAR T autoimmune push